Overall research objective is to make a valuable contribution to a better understanding and identification of patients with a liver disease who will experience disease progression or may effectively respond to treatment.
Of particular focus is development of individualized prediction models of complicated follow-up survival data to be applied in the daily medical practice in the field of liver diseases. In parallel a major interest is to initiate and coordinate International and National platforms for specialised scientists allowing collaboration across borders for a deeper understanding of specific areas within liver disease.
- Senior Biostatistician of Clinical Research Studies at Toronto Centre for Liver Disease. Supervising MSc, PhD and fellows in conduction of clinical research.
- Coordinator of large National and International research studies for antiviral treatment for viral hepatitis: HBV 99-01, VIRID, PARC, ARES, PEGON, GIANT-B, PAS, PEGON, HCV Cohort Study, NIH-studies, the Toronto Viral Hepatitis Care Network (VIRCAN) and autoimmune liver disease: the Global PBC Group, the International PSC study group and the Canadian Network for Autoimmune Liver Disease (CaNAL).
- Principal Investigator of the Global PBC Group, CaNAL, and NAPPED.
- Senior Biostatistician, Toronto Centre for Liver Disease, Toronto General Hospital
- Senior Biostatistician and Associate Professor, Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam the Netherlands